Ipilimumab (Yervoy®) is a monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), one of the checkpoints that regulates the immune system. CTLA-4 is a negative regulator of T-cell activation and proliferation, which means that it turns the immune response “off.” Ipilimumab binds to CTLA-4, essentially cutting the brake, thereby enabling the immune system to remain “on” and better attack developing cancers.

Ipilimumab is indicated as a monotherapy for unresectable or metastatic (advanced) melanoma and as an adjuvant treatment of resected stage 3 melanoma. Ipilimumab is also indicated in combination with nivolumab (Opdivo®) for the treatment of unresectable or metastatic melanoma (discussed in a separate nursing tool).

This document is part of an overall nursing toolkit intended to assist nurses in optimizing management of melanoma patients receiving newer anti-melanoma therapies.
• A higher ipilimumab dose and longer treatment duration is employed when ipilimumab is used as an adjuvant therapy than as a monotherapy for advanced melanoma. The regimens are indicated below:

![Ipilimumab for Advanced Melanoma: Regimen Dosing Schedule](image)

- **Ipilimumab**
  - (IV Infusion over 90 minutes)
  - **Total of 4 cycles of ipilimumab (every 3 weeks)**

  - **Dose 1**: 3 mg/kg
  - **Dose 2**: 3 mg/kg
  - **Dose 3**: 3 mg/kg
  - **Dose 4**: 3 mg/kg

*In the event of toxicity, doses may be delayed, but all treatment should be administered within 16 weeks of the first dose.*
**DRUG-DOSING/ADMINISTRATION**

(Continued)

*Ipilimumab Adjuvant Therapy for Resected Stage 3 Melanoma: Regimen Dosing Schedule*

- Obtain pretreatment laboratory tests (e.g., adrenal function [ACTH], clinical chemistries, liver function tests, and thyroid function tests) prior to initiation of therapy and before each cycle.

- Ipilimumab is a clear to opalescent, colorless to pale-yellow solution. Discard the vial if solution is cloudy, discolored, or contains extraneous particulate matter (other than a few translucent-to-white, proteinaceous particles).

- Do not shake the vial and do not coadminister ipilimumab with other drugs through the same intravenous line. It is important to assure IV access before administration. Administer ipilimumab through an intravenous line containing a sterile, non-pyrogenic, low-protein-binding in-line filter (we recommend a pore size of 0.2–4 micrometers).

*In the event of toxicity, doses are omitted, not delayed.*

---

Note: A recent phase 3 study report from ASCO 2017 indicated an adjuvant ipilimumab dose of 10 mg/kg was associated with higher rates of treatment-related adverse events than a lower 3 mg/kg dose in patients with resected high-risk melanoma, without improving recurrence-free survival.
SIDE EFFECTS AND THEIR MANAGEMENT

Because ipilimumab is an immunotherapy that works by enhancing the patient’s immune system, most adverse reactions associated with ipilimumab are related to overactivity of the patient’s immune system (ie, immune-related adverse events [irAEs]). Various organ systems (often more than one) or tissues may be affected.

• Key to toxicity management:
  » Proactive assessment for early signs/symptoms of toxicity
  » Prompt intervention
  » irAEs are typically managed with selective use of steroids
  » In rare instances, toxicity may be steroid refractory, and additional immunosuppressive agents may be necessary (mycophenolate mofetil, cyclophosphamide, etc)
  » Ipilimumab will likely be held or discontinued depending on severity and/or persistence
  » Referral to organ specialist should be considered

• irAEs associated with ipilimumab treatment can be categorized into those that are most common, less common but serious, and others that are easily overlooked

• Table 1 lists these irAEs and the corresponding Care Step Pathways in Appendix 1. Other adverse events associated with ipilimumab are shown in Appendix 2

Table 1. Care Step Pathways for the Management of Immune-Related AEs Associated With Ipilimumab Monotherapy

<table>
<thead>
<tr>
<th>irAE category</th>
<th>Examples</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Most common</td>
<td>Skin toxicities (pruritis, rash)</td>
<td>Appendix 1</td>
</tr>
<tr>
<td></td>
<td>Gastrointestinal toxicities</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Mild diarrhea/colitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Mucositis/xerostomia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatic toxicities</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Elevated transaminases</td>
<td></td>
</tr>
<tr>
<td>Less common but serious</td>
<td>Endocrinopathies</td>
<td>Appendix 1</td>
</tr>
<tr>
<td></td>
<td>- Hypophysitis (pituitary)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Thyroiditis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Diabetes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pneumonitis</td>
<td></td>
</tr>
<tr>
<td>Easily overlooked</td>
<td>Arthralgia/arthritis</td>
<td>Appendix 1</td>
</tr>
<tr>
<td></td>
<td>Neuropathy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nephritis</td>
<td></td>
</tr>
</tbody>
</table>
Ipilimumab-related irAEs may occur at any time, including after treatment completion or discontinuation. Continuing to monitor patients is critical.

Patients sometimes experience signs/symptoms that they think are due to “flu” or a cold, but that actually represent an irAE or an infusion reaction.

Endocrinopathies often present with vague symptoms (fatigue, headache, and/or depression) that can easily be overlooked or initially misdiagnosed. Hypervigilance and follow-up is important on the part of both nurses and patients.

IrAEs may become apparent upon tapering of corticosteroids, since they can be suppressed or masked by immunosuppressive therapy. Patients should be advised to be on the lookout for early signs of irAEs during the tapering period.

Unlike other irAEs, endocrinopathies usually do not resolve and may require lifelong hormone replacement therapy.

Nurses should encourage patients to carry information about their ipilimumab regimen with them at all times. This might be the ipilimumab-specific wallet card, or at least emergency phone numbers and the side effects associated with the regimen. You may suggest that they paperclip the wallet and insurance cards together so information about their regimen will be shared whenever they show their insurance card.

Advise patients to take pictures of any skin lesions for documentation.
Q. Is ipilimumab monotherapy still being used in the advanced melanoma setting?

A. Yes. While PD1 inhibitors and the combination of ipilimumab and nivolumab are more typically used, there are some patients who still receive ipilimumab monotherapy for unresectable or metastatic melanoma. In fact, the ipilimumab label was recently expanded to include use in pediatric patients age 12 and older with advanced melanoma.

Q. How do I counsel my patients about immunizations?

A. That’s a logical question, given that the checkpoint inhibitors alter the immune response. Advise your patients not to receive live vaccines (eg, measles, mumps, and rubella and the varicella vaccine [Zostavax®]) because they have not been evaluated in this setting. The use of attenuated vaccines has been and continues to be evaluated. Counsel patients to discuss all immunizations with the oncology team prior to administration so the benefits and risks can be weighed on an individual basis. For example, Shingrix®, approved in 2017, is an attenuated (non-live) varicella vaccine, which can be discussed with the oncology team if a recommendation is being made for the patient to receive the injection series.
PATIENT RESOURCES

Financial Assistance
BMS Access Support
1 (800) 861-0048
http://www.bmsaccesssupport.bmscustomerconnect.com/patient

Additional Information Resources
AIM at Melanoma Foundation (Nurse on Call, patient symposia, drug resources, etc)
http://www.AIMatMelanoma.org

American Cancer Society Resource Section
ADDITIONAL RESOURCES


• Food and Drug Administration & Bristol-Myers Squibb. Risk Evaluation and Mitigation Strategy (REMS) for ipilimumab (Yervoy); February 2012. Includes wallet card etc. Available at: https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM249435.pdf


Click here for downloadable action plans to customize for your patients
Care Step Pathway - Skin Toxicities

Nursing Assessment

**Look:**
- Does the patient appear uncomfortable?
- Does the patient appear unwell?
- Is there an obvious rash?
- Is the patient scratching during the visit?
- Is skin integrity intact?
- Are there skin changes?
  - Xerosis
  - Changes in skin pigment or color
- Is there oral involvement of the rash?

**Listen:**
- Does the patient have pruritus with or without rash?
  - Is there a rash with or without pruritus?
- Are symptoms interfering with ADLs?
- With sleep?
- Have symptoms worsened?

**Recognize:**
- Is there a history of dermatitis, pre-existing skin issues (psoriasis, wounds, etc.)?
- Laboratory abnormalities consistent with other etiologies (e.g., eosinophils on complete blood count, liver function abnormalities)

Grading Toxicity

**MACULOPAPULAR RASH (aka morbilliform rash)**
Definition: A disorder characterized by the presence of macules (flat) and papules (elevated); frequently affecting the upper trunk, spreading centripetally and associated with pruritus

<table>
<thead>
<tr>
<th>Grade 1 (Mild)</th>
<th>Grade 2 (Moderate)</th>
<th>Grade 3 (Severe)</th>
<th>Grade 4 (Potentially Life-Threatening)</th>
<th>Grade 5 (Death)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macules/papules covering &lt;10% BSA with or without symptoms (e.g., pruritus, burning, tightness)</td>
<td>Macules/papules covering 10-30% BSA with or without symptoms (e.g., pruritus, burning, tightness); limiting instrumental ADLs</td>
<td>Macules/papules covering &gt;30% BSA with or without associated symptoms; limiting self-care ADLs; skin sloughing covering &lt;10% BSA</td>
<td>Papules/pustules covering any % BSA with or without symptoms and associated with superinfection requiring IV antibiotics; skin sloughing covering 10-30% BSA</td>
<td></td>
</tr>
</tbody>
</table>

**PRURITUS**
Definition: A disorder characterized by an intense itching sensation

<table>
<thead>
<tr>
<th>Grade 1 (Mild)</th>
<th>Grade 2 (Moderate)</th>
<th>Grade 3 (Severe)</th>
<th>Grade 4 (Potentially Life-Threatening)</th>
<th>Grade 5 (Death)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild or localized; topical intervention indicated</td>
<td>Intense or widespread; intermittent; skin changes from scratching (e.g., edema, papulation, excoriations, lichenification, oozing/crusts); limiting instrumental ADLs</td>
<td>Intense or widespread; constant; limiting self-care ADL or sleep</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Management

Overall Strategy
- Assess for other etiology of rash: ask patient about new medications, herbals, supplements, alternative/complementary therapies, lotions, etc.

Intervention in at-risk patients
- Advise gentle skin care:
  o Avoid soap. Instead, use non-soap cleansers that are fragrance- and dye-free (use mild soap on the axillae, genitalia, and feet)
  o Daily applications of non-steroidal moisturizers or emollients containing humectants (urea, glycerin)
  o Apply moisturizers and emollients in the direction of hair growth to minimize development of folliculitis
- Advise sun-protective measures
- Assess patient & family understanding of prevention strategies and rationale
  o Identify barriers to adherence

Grade 1 (Mild)
- Immunotherapy to continue
- Oral antihistamines will be used in some patients
- Topical corticosteroids will be used in some patients
- Advise vigilant skin care
  o Increase to twice daily applications of non-steroidal moisturizers or emollients applied to moist skin
  o Moisturizers with ceramides and lipids are advised; however, if cost is an issue, petroleum jelly is also effective
  o Soothing methods
    ▪ Cool cloth applications
    ▪ Topicals with cooling agents such as menthol or camphor
    ▪ Refrigerating products prior to application
  o Avoid hot water; bathe or shower with tepid water
  o Keep fingernails short
  o Cool temperature for sleep
- Advise strict sun protection
- Monitor vigilantly. Instruct patient & family to call clinic with any sign of worsening rash/symptoms. Anticipate office visit for evaluation
- Assess patient & family understanding of skin care recommendations and rationale
  o Identify barriers to adherence

Grade 2 (Moderate)
- Ipilimumab will be withheld for any Grade 2 event
- Oral corticosteroids (0.5 mg/kg–1.0 mg/kg) and oral antihistamines/oral anti-pruritics to be used
- Consider dermatology consult
- Patient education:
  o Proper administration of oral corticosteroids
    ▪ Take with food
    ▪ Take early in day
  o Concomitant medications may be prescribed
    ▪ H2 blocker
    ▪ Antibiotic prophylaxis
- Advise vigilant skin care
  o Gentle skin care
  o Tepid baths; oatmeal baths
- Advise strict sun protection
- Assess patient & family understanding of toxicity and rationale for treatment hold
  o Identify barriers to adherence

Grades 3-4 (Severe or Life-Threatening)
- Nivolumab to be withheld for Grade 3 rash or confirmed SJS or TEN
- Ipilimumab to be discontinued for any Grade 3/4 event, and nivolumab for Grade 4 rash or confirmed SJS or TEN
- Pembrolizumab or nivolumab to be discontinued for any Grade 3/4 event that recurs, persists ≥12 weeks, or for inability to reduce steroid dose to ≤10 mg prednisone or equivalent within 12 weeks
- Anticipate hospitalization and initiation of IV corticosteroids (1.5–2.0 mg/kg)
- Anticipate dermatology consult +/- biopsy
- Provide anticipatory guidance:
  o Rationale for hospitalization and treatment discontinuation
  o Rationale for prolonged steroid taper
  o Side effects of high-dose steroids
  o Risk of opportunistic infection and need for antibiotic prophylaxis
  o Effects on blood sugars, muscle atrophy, etc.
- Assess patient & family understanding of toxicity and rationale for treatment discontinuation
  o Identify barriers to adherence, specifically compliance with steroids when transitioned to oral corticosteroids

RED FLAGS:
- Extensive rash (>50% BSA), or rapidly progressive
- Oral involvement
- Concern for suprainfection

ADLs = activities of daily living; BSA = body surface area; SJS = Stevens-Johnson syndrome; TEN = toxic epidermal necrolysis
Care Step Pathway - Gastrointestinal Toxicity: Diarrhea and Colitis

Nursing Assessment

Look:
- Does the patient appear weak?
- Has the patient lost weight?
- Does the patient appear dehydrated?
- Does the patient appear in distress?

Listen:
- Quantity & quality of bowel movements (e.g., change in/ increased frequency over baseline): solid, soft, or liquid diarrhea; dark or bloody stools; or stools that float
- Fever
- Abdominal pain or cramping
- Increased fatigue
- Upset stomach, nausea, or vomiting
- Bloating/increased gas
- Decreased appetite or food aversions

Recognize:
- Serum chemistry/hematology abnormalities
- Infectious vs immune-related adverse event causation
- Peritoneal signs of bowel perforation (i.e., pain, tenderness, bloating)

Grading Toxicity

Diarrhea (increased frequency, loose, large volume, or liquidy stools)

Grade 1 (Mild)
- Increase of <4 stools/day over baseline
- Mild increase in ostomy output compared with baseline

Grade 2 (Moderate)
- Increase of 4–6 stools/day over baseline
- Moderate increase of output in ostomy compared with baseline

Grade 3 (Severe)
- Increase of ≥7 stools/day over baseline; incontinence
- Hospitalization indicated
- Severe increase in ostomy output compared with baseline
- Limiting self-care ADLs

Grade 4 (Potentially Life-Threatening)
- Life-threatening (e.g., perforation, bleeding, ischemic necrosis, toxic megacolon)
- Urgent intervention required

Grade 5 (Death)

Colitis (inflammation of the intestinal lining)

Grade 1 (Mild)
Asymptomatic; clinical or diagnostic observation only; intervention not indicated

Grade 2 (Moderate)
Abdominal pain; blood or mucus in stool

Grade 3 (Severe)
Severe abdominal pain; change in bowel habits; medical intervention indicated; peritoneal signs

Grade 4 (Potentially Life-Threatening)
Life-threatening (e.g., hemodynamic collapse); urgent intervention indicated

Grade 5 (Death)
Management (including Anticipatory Guidance)

**Overall Strategy:**
- Rule out infectious, non-infectious, disease-related etiologies

**Grade 1 (Mild)**
- May continue immunotherapy

**Diet modifications (very important):**
- Institute bland diet; decrease fiber, uncooked fruits/vegetables, red meats, fats, dairy, oil, caffeine, alcohol, sugar

**Grade 2 (Moderate)**
- Send stool sample for *Clostridium difficile* testing, culture, and ova and parasite
- Immunotherapy to be withheld until Grade ≤1 or patient’s baseline (ipilimumab, pembrolizumab, nivolumab)
- Provide anti-diarrheals: Imodium® (loperamide) or Lomotil® (diphenoxylate/atropine)
- If upper or lower GI symptoms persist >5–7 days
  - Oral steroids* to be started (prednisone 0.5 mg–1 mg/kg/day or equivalent)
  - After control of symptoms, a ≥4-week steroid* taper will be initiated
- Immunotherapy to be discontinued if Grade 2 symptoms persist ≥6 weeks (ipilimumab) or ≥12 weeks (pembrolizumab, nivolumab), or for inability to reduce steroid dose to ≤7.5 mg (ipilimumab) or ≤10 mg prednisone or equivalent (pembrolizumab, nivolumab) within 12 weeks

**Diet modification:**
- Institute bland diet low in fiber, residue, and fat (BRAT [Bananas, Rice, Applesauce, Toast] diet)
- Decrease fiber, uncooked fruit and vegetables, red meats, fats, dairy, oil, caffeine, alcohol, sugar
- Avoid laxatives or stool softeners
- Advance diet slowly as steroids are tapered,* reduced to low doses and assess for loose or liquid stool for several days or longer
- Steroids* to be tapered slowly over at least 4 weeks

**(Moderate) persistent or relapsed symptoms with steroid* taper**
- Consider gastroenterology consult for possible intervention (flex sig/colonoscopy/endoscopy)
- IV steroids* to be started at 1 mg/kg/day
- Immunotherapy to be held until ≤Grade 1
- Control symptoms, then ≥4-week steroid* taper
- Recurrent diarrhea is more likely when treatment is restarted

**Grades 3-4 (Severe or Life-Threatening)**
- Onset:
  - Continued diet modification, anti-diarrheals, and steroid titration
- Immunotherapy:
  - Grade 3: Pembrolizumab or nivolumab to be withheld when used as single agent; ipilimumab to be discontinued as single agent and nivolumab when given with ipilimumab
  - Grade 4: Ipilimumab and/or PD-1 inhibitor to be discontinued
- Dosage of steroids* to be increased:
  - Steroids* 1-2 mg/kg/day prednisone or equivalent: methylprednisolone (Solu-Medrol®) 1 g IV (daily divided) doses
- Hospitalization
- GI consultation
- Assess for peritoneal signs, perforation (NPO & abdominal key, surgical consult prn)
- Use caution with analgesics (opioids) and anti-diarrheal medications

**Steroid* refractory:** (if not responsive within 72 hours to high-dose IV steroid* infusion)
- Infliximab (Remicade®) 5 mg/kg infusion may be considered
- May require ≥1 infusion to manage symptoms (may re-administer at week 2 & week 6)
- Avoid with bowel perforation or sepsis
- PPD (tuberculin) testing not required in this setting
- Infliximab infusion delay may have life-threatening consequences

**Diet modification:**
- Very strict with acute symptoms: clear liquids; very bland, low fiber and low residue (BRAT diet)
- Advance diet slowly as steroids* reduced to low doses
- Steroids* to be tapered slowly over at least 4 weeks
- **Supportive medications for symptomatic management:**
  - Loperamide: 2 capsules at the onset & 1 with each diarrhea stool thereafter, with a maximum of 6 per day
  - Diphenoxylate/atropine 1-4 tablets per day
  - Simethicone when necessary

---

**Dietary Recommendations for Diarrhea**

- Early identification and evaluation of patient symptoms
- *Steroid taper instructions/calendars as a guide but not an absolute
- Recurrent diarrhea is more likely when treatment is
- Steroids* to be tapered slowly over at least 4 weeks
- 4-week steroid* taper
- **Grades 1**
  - Immunotherapy to be held
- **Grades 2**
  - Immunotherapy to be discontinued if Grade 2 symptoms persist ≥6 weeks (ipilimumab) or ≥12 weeks (pembrolizumab, nivolumab), or for inability to reduce steroid dose to ≤7.5 mg (ipilimumab) or ≤10 mg prednisone or equivalent (pembrolizumab, nivolumab) within 12 weeks
- **Dietary Modifications**
  - Institute bland diet; decrease fiber, uncooked fruits/vegetables, red meats, fats, dairy, oil, caffeine, alcohol, sugar
- Decrease fiber, uncooked fruit and vegetables, red meats, fats, dairy, oil, caffeine, alcohol, sugar
- Avoid laxatives or stool softeners
- Advance diet slowly as steroids are tapered,* reduced to low doses and assess for loose or liquid stool for several days or longer
- Steroids* to be tapered slowly over at least 4 weeks
- Consider gastroenterology consult for possible intervention (flex sig/colonoscopy/endoscopy)
- IV steroids* to be started at 1 mg/kg/day
- Immunotherapy to be held until ≤Grade 1
- Control symptoms, then ≥4-week steroid* taper
- Recurrent diarrhea is more likely when treatment is restarted
- **Supportive Medications**
  - Loperamide: 2 capsules at the onset & 1 with each diarrhea stool thereafter, with a maximum of 6 per day
  - Diphenoxylate/atropine 1-4 tablets per day
  - Simethicone when necessary

**Gastrointestinal Toxicity**

© 2017 The Melanoma Nursing Initiative. All rights reserved

www.themelanomanurse.org
**Nursing Implementation:**
- Compare baseline assessment: grade & document bowel frequency
- Early identification and evaluation of patient symptoms
- Grade symptom & determine level of care and interventions required
- Early intervention with lab work and office visit if colitis symptoms are suspected

*Steroid taper instructions/calendar as a guide but not an absolute*
- Taper should consider patient’s current symptom profile
- Close follow-up in person or by phone, based on individual need & symptomatology
- Anti-acid therapy daily as gastric ulcer prevention while on steroids
- Review steroid medication side effects: mood changes (anger, reactive, hyperaware, euphoric, mania), increased appetite, interrupted sleep, oral thrush, fluid retention
- Be alert to recurring symptoms as steroids taper down & report them (taper may need to be adjusted)

**Long-term high-dose steroids:**
- Consider antimicrobial prophylaxis (sulfamethoxazole/trimethoprim double dose MW/F; single dose if used daily) or alternative if sulfa-allergic (e.g., atovaquone [Mepron®] 1500 mg po daily)
- Consider additional antiviral and antifungal coverage
- Avoid alcohol/acetaminophen or other hepatoxins

**RED FLAGS:**
- Change in gastrointestinal function, decreased appetite
- Bloating, nausea
- More frequent stools, consistency change from loose to liquid
- Abdominal pain
- Fever

ADLs = activities of daily living; PD-1 = programmed cell death protein 1
### Nursing Assessment

**Look:**
- Does the patient appear uncomfortable?
- Does the patient appear unwell?
- Difficulty talking?
- Licking lips to moisten often?
- Weight loss?
- Does the patient appear dehydrated?
- Does the patient have thrush?

**Listen:**
- Does the patient report?
  - Mouth pain (tongue, gums, buccal mucosa)
  - Mouth sores
  - Difficulty eating
  - Waking during the sleep to sip water
  - Recent dental-related issues
  - Need for dental work (e.g., root canal, tooth extraction)
  - Have symptoms worsened?

**Recognize:**
- A history of mouth sores
- Does patient smoke?
- Concomitant medications associated with causing dry mouth?
- Reports of dry mouth often accompany mucositis
- Other reports of dry membranes (e.g., eyes, nasal passages, vagina)

### Grading Toxicity

**Oral Mucositis**

Definition: A disorder characterized by inflammation of the oral mucosa

<table>
<thead>
<tr>
<th>Grade 1 (Mild)</th>
<th>Grade 2 (Moderate)</th>
<th>Grade 3 (Severe)</th>
<th>Grade 4 (Potentially Life-Threatening)</th>
<th>Grade 5 (Death)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic or mild symptoms; intervention not indicated</td>
<td>Moderate pain; not interfering with oral intake; modified diet indicated</td>
<td>Severe pain; interfering with oral intake</td>
<td>Life-threatening consequences; urgent intervention indicated</td>
<td></td>
</tr>
</tbody>
</table>

**Xerostomia (dry mouth)**

Definition: A disorder characterized by reduced salivary flow in the oral region

<table>
<thead>
<tr>
<th>Grade 1 (Mild)</th>
<th>Grade 2 (Moderate)</th>
<th>Grade 3 (Severe)</th>
<th>Grade 4 (Potentially Life-Threatening)</th>
<th>Grade 5 (Death)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptomatic (e.g., dry or thick saliva) without significant dietary alteration; unstimulated saliva flow &gt;0.2 mL/min</td>
<td>Moderate symptoms; oral intake alterations (e.g., copious water, other lubricants, diet limited to purees and/or soft, moist foods); unstimulated saliva 0.1 to 0.2 mL/min</td>
<td>Inability to adequately aliment orally; tube feeding or total parenteral nutrition indicated; unstimulated saliva &lt;0.1 mL/min</td>
<td>Life-threatening consequences; urgent intervention indicated</td>
<td></td>
</tr>
</tbody>
</table>
Management (Including anticipatory guidance)

Overall Strategy
- Assess for other etiology of mucositis or dry mouth: candidiasis; ask patient about new medications (particularly antihistamines), herbas, supplements, alternative/complementary therapies

Interventions in at-risk patients
- Advise basic oral hygiene:
  - Tooth brushing (soft toothbrush, avoid toothpaste with whitening agents)
  - Use of dental floss daily
  - >1 mouth rinses to maintain oral hygiene (avoid commercial mouthwashes or those with alcohol)
- If patient wears dentures, assess for proper fit, areas of irritation, etc.
- Dental referral if necessary
- Assess patient & family understanding of prevention strategies and rationale
  - Identify barriers to adherence

Grade 1 (Mild)
- Anticipate immunotherapy to continue
- Advise ongoing basic oral hygiene
- Advise avoidance of hot, spicy, acidic foods
- Anticipate possible alternative treatment(s)
  - Zinc supplements or 0.2% zinc sulfate mouthwash
  - Probiotics with Lactobacillus
  - Benzydamine HCl
- Assess patient & family understanding of recommendations and rationale
  - Identify barriers to adherence

Grade 2 (Moderate)
- Ipiplimumab to be withheld for any Grade 2 event (resume when Grade 0/1)
- Immunotherapy to be discontinued for Grade 2 events persisting ≥6 (ipiplimumab) or ≥12 weeks (pembrolizumab, nivolumab)
- Assess for Sicca syndrome, Sjögren’s syndrome
- Encourage vigilant oral hygiene

Xerostomia:
- Advise moistening agents
  - Saliva substitute
  - Synthetic saliva
  - Oral lubricants
- Advise secretagogues
  - Nonpharmacologic
    - Sugarless gum
    - Sugarless hard candies
    - Natural lemon
  - Pharmacologic
    - Pilocarpine
    - Cevimeline HCl

Mucositis:
- Vigilant oral hygiene
  - Increase frequency of brushing to Q4 hours and at bedtime
  - If unable to tolerate brushing, advise chlorhexidine gluconate 0.12% or sodium bicarbonate rinses
    - 1 tsp baking soda in 8 ounces of water or
    - ½ tsp salt and 2 tbsp sodium bicarbonate dissolved in 4 cups of water
- Encourage sips of cool water or crushed ice
  - Encourage soft, bland non-acidic foods
  - Anticipatory guidance regarding use of pharmacologic agents (as applicable)
    - Analgesics
      - Gelclair®, Zilactin®
      - 2% viscous lidocaine applied to lesions 15 minutes prior to meals
      - 2% morphine mouthwash
      - 0.5% doxepin mouthwash
      - “Miracle Mouthwash”: diphenhydramine/lidocaine/simethicone
    - Corticosteroid rinses
      - Dexamethasone oral solution
  - Monitor weight
  - Nutrition referral if appropriate

Grade 3-4 (Severe or Life-Threatening)
- Nivolumab to be withheld for first occurrence Grade 3 event. Immunotherapy to be continued for any Grade 4 event or for a Grade 3 event persisting ≥12 weeks (ipiplimumab, pembrolizumab, nivolumab) or any recurrent Grade 3 event (pembrolizumab, nivolumab)
- Anticipate hospitalization if unable to tolerate oral solids or liquids
- Unclear role of systemic corticosteroids
- Anticipate need for supplemental nutrition
  - Enteral
  - Parenteral
- Anticipatory guidance regarding use of pharmacologic agents
  - Analgesics
    - Systemic opioids may be indicated
- Oral care
- Assess patient & family understanding of toxicity and rationale for interventions as well as treatment discontinuation
  - Identify barriers to adherence

Mucositis Xerostomia Page 2 of 2
### Care Step Pathway – Hepatotoxicity (immunotherapy-induced inflammation of liver tissue)

#### Nursing Assessment

**Look:**
- Does the patient appear fatigued or listless?
- Does the patient appear jaundiced?
- Does the patient appear diaphoretic?
- Does the patient have any ascites?

**Listen:**
- Change in energy level?
- Change in skin color? Yellowing?
- Change in stool color (paler)?
- Change in urine color (darker/tea colored)?
- Abdominal pain: specifically, right upper quadrant pain?
- Bruising or bleeding more easily?
- Fevers?
- Change in mental status?
- Increased sweating?

**Recognize:**
- Elevation in LFTs
  - AST/SGOT
  - ALT/SGPT
  - Bilirubin (total/direct)
- Alteration in GI function
- Symptoms such as abdominal pain, ascites, somnolence, and jaundice
- Other potential causes (viral, drug toxicity, disease progression)

#### Grading Toxicity: ULN

<table>
<thead>
<tr>
<th>Grade 1 (Mild)</th>
<th>Grade 2 (Moderate)</th>
<th>Grade 3 (Severe)</th>
<th>Grade 4 (Potentially Life-Threatening)</th>
<th>Grade 5 (Death)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST/ALT: &gt;ULN – 3.0× ULN</td>
<td>AST/ALT: &gt;3.0× – 5.0× ULN</td>
<td>AST/ALT: &gt;5.0× – 20.0× ULN</td>
<td>AST/ALT: &gt;20× ULN</td>
<td></td>
</tr>
<tr>
<td>Bilirubin: &gt;ULN – 1.5× ULN</td>
<td>Bilirubin: &gt;1.5× – 3.0× ULN</td>
<td>Bilirubin: &gt;3.0× ULN</td>
<td>Bilirubin: &gt;10× ULN</td>
<td></td>
</tr>
</tbody>
</table>
**Management (including anticipatory guidance)**

**Overall Strategy:**
- LFTs should be checked and results reviewed prior to each dose of immunotherapy
- Rule out infectious, non-infectious, and malignant causes. Consider assessing for new onset or re-activation of viral hepatitis, medications (acetaminophen, statins, and other hepatotoxic meds, or supplements/herbals), recreational substances (alcohol); consider disease progression

Infliximab infusions are not recommended due to potential hepatotoxic effects

<table>
<thead>
<tr>
<th>Grade 1 (Mild)</th>
<th>Grade 2 (Moderate)</th>
<th>Grade 3 (Severe)</th>
<th>Grade 4 (Life-Threatening)</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Immunotherapy may be withheld if LFTs are trending upward; recheck LFTs within ~ 1 week</td>
<td>- Immunotherapy to be withheld; recheck LFTs daily x 3 days or every 3 days; to be resumed when complete/partial resolution of adverse reaction (Grade 0/1)</td>
<td>- Steroids* to be initiated at 2 mg/kg/day prednisone or equivalent daily oral</td>
<td>- Immunotherapy to be discontinued</td>
</tr>
<tr>
<td></td>
<td>- Immunotherapy to be discontinued for Grade 2 events lasting ≥6 (ipilimumab) or ≥12 weeks (pembrolizumab, nivolumab), or for inability to reduce steroid dose to 7.5 mg prednisone or equivalent per day</td>
<td>- Nivolumab to be withheld for first-occurrence Grade 3 event. Ipilimumab to be discontinued for any Grade 3 event, and nivolumab or pembrolizumab for any recurrent Grade 3 event or Grade 3 event persisting ≥12 weeks</td>
<td>- Hospital admission</td>
</tr>
<tr>
<td></td>
<td>- Consider starting steroids* 0.5 mg – 1 mg/kg/day prednisone or equivalent daily (IV methylprednisolone 125 mg total daily dose) + an anti-acid</td>
<td>- Admission for IV steroids*</td>
<td>- Steroids* to be initiated at 2 mg/kg/day prednisone or equivalent daily intravenous</td>
</tr>
<tr>
<td></td>
<td>- Consider hospital admission for IV steroids*</td>
<td>- R/O hepatitis infection (acute infection or reactivation)</td>
<td>- R/O hepatitis infection</td>
</tr>
<tr>
<td></td>
<td>- If LFT normalized and symptoms resolved, steroids* to be tapered over ≥ 4 weeks when function recovers</td>
<td>- Daily LFTs</td>
<td>- Daily LFTs</td>
</tr>
<tr>
<td></td>
<td>- Once patient returns to baseline or Grade 0-1, consider resuming treatment</td>
<td>- If sustained elevation is significant and/or refractory to steroids* potential for ADDING to steroid regimen</td>
<td>- If sustained elevation and refractory to steroids* potential for ADDING to steroid regimen:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Hepatology/gastroenterology consult</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Consider liver biopsy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- If LFTs stable/declining daily for 5 consecutive days: decrease LFT checks to q 3 days, then weekly</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- If LFT normalized and symptoms resolved, steroids* to be tapered slowly over ≥4 weeks</td>
</tr>
</tbody>
</table>

**Hepatotoxicity**

*Note: LFT = liver function test; SGOT = aspartate aminotransferase; SGPT = alanine aminotransferase; AST = aspartate aminotransferase; ALT = alanine aminotransferase; GI = gastrointestinal*
Nursing Implementation:
- Review LFT results prior to administration of immunotherapy
- Early identification and evaluation of patient symptoms
- Early intervention with lab work and office visit if hepatotoxicity is suspected
- Grade LFTs and any other accompanying symptoms

*Steroid taper instructions/calendar as a guide but not an absolute
- Taper should consider patient’s current symptom profile
- Close follow-up in person or by phone, based on individual need & symptomatology
- Anti-acid therapy daily as gastric ulcer prevention while on steroids
- Review steroid medication side effects: mood changes (anger, reactive, hyperaware, euphoric, mania), increased appetite, interrupted sleep, oral thrush, fluid retention
- Be alert to recurring symptoms as steroids taper down & report them (taper may need to be adjusted)

Long-term high-dose steroids:
- Consider antimicrobial prophylaxis (sulfamethoxazole/trimethoprim double dose M/W/F; single dose if used daily) or alternative if sulfa-allergic (e.g., atovaquone [Mepron®] 1500 mg po daily)
- Consider additional antiviral and antifungal coverage
- Avoid alcohol/acetaminophen or other hepatotoxins

RED FLAGS:
- Severe abdominal pain, ascites, somnolence, jaundice, mental status changes

ALT = alanine aminotransferase; AST = aspartate aminotransferase; GI = gastrointestinal; LFT = liver function test; SGOT - serum glutamic oxaloacetic transaminase; SGPT = serum glutamic pyruvic transaminase; ULN = upper limit of normal
Hypophysitis Page 1 of 2

Care Step Pathway – Hypophysitis (inflammation of the pituitary gland)

Nursing Assessment

Look:
- Does the patient appear fatigued?
- Does the patient look listless?
- Does the patient look ill?
- Does the patient look uncomfortable?

Listen:
- Does the patient report:
  o Change in energy?
  o Headache?
  o Dizziness?
  o Nausea/vomiting?
  o Altered mental status?
  o Visual disturbances?
  o Fever?

Recognize:
- Low levels of hormones produced by pituitary gland (ACTH, TSH, FSH, LH, GH, prolactin)
- Brain MRI with pituitary cuts: enhancement and swelling of the pituitary gland.
- DDX adrenal Insufficiency: low cortisol and high ACTH
- DDX primary hypothyroidism: low free T4 and high TSH

Grading Toxicity (Overall)

Grade 1 (Mild)
Asymptomatic or mild symptoms; clinical or diagnostic observation only (headache, fatigue)

Grade 2 (Moderate)
Moderate symptoms; limiting age-appropriate instrumental ADLs (headache, fatigue)

Grade 3 (Severe)
Severe or medically significant symptoms; limiting self-care ADL (sepsis, severe ataxia)

Grade 4 (Potentially Life-Threatening)
Urgent intervention required (sepsis, severe ataxia)

Grade 5 (Death)

Management

Overall Strategy:
- Ipilimumab to be withheld for any symptomatic hypophysitis and discontinued for symptomatic reactions persisting ≥6 weeks or for inability to reduce steroid dose to ≤7.5 mg prednisone or equivalent per day
- Nivolumab to be withheld for Grade 2/3 hypophysitis and discontinued for Grade 4 hypophysitis. Pembrolizumab to be withheld for Grade 2 hypophysitis and withheld or discontinued for Grade 3/4 hypophysitis
- 1 mg/kg methylprednisolone (or equivalent) IV to be given daily
  o If given during acute phase, may reverse inflammatory process
- To be followed with prednisone 1-2 mg/kg daily with gradual tapering over at least 4 weeks
- Long-term supplementation of affected hormones is often required
  o Secondary hypothyroidism requiring levothyroxine replacement
  o Secondary hypoadrenalism requiring replacement hydrocortisone
    ▪ Typical dose: 20 mg qAM and 10 mg qPM
- Assess risk of opportunistic infection based on duration of steroid taper (and consider prophylaxis if needed)
- Collaborative management approach with endocrinology (particularly if permanent loss of organ function)

ACTH = adrenocorticotropic hormone; ADLs = activities of daily living; DDX = differential diagnosis; FSH = follicle-stimulating hormone; GH = growth hormone; LH = luteinizing hormone; MRI = magnetic resonance imaging; TSH = thyroid stimulating hormone.
Nursing Assessment

Care Step Pathway – Hypophysitis (inflammation of the pituitary gland)

Look:
- Does the patient appear fatigued?
- Does the patient look listless?
- Does the patient look ill?
- Does the patient look uncomfortable?

Listen:
- Does the patient report:
  - Change in energy?
  - Headache?
  - Dizziness?
  - Nausea/vomiting?
  - Altered mental status?
  - Visual disturbances?
  - Fever?

Recognize:
- Low levels of hormones produced by pituitary gland (ACTH, TSH, FSH, LH, GH, prolactin)
- Brain MRI with pituitary cuts: enhancement and swelling of the pituitary gland.
- DDX adrenal Insufficiency: low cortisol and high ACTH
- DDX primary hypothyroidism: low free T4 and high TSH

Management

Overall Strategy:
- Ipilimumab to be withheld for any symptomatic hypophysitis and discontinued for symptomatic reactions persisting ≥ 6 weeks or for inability to reduce steroid dose to ≤ 7.5 mg prednisone or equivalent per day
- Nivolumab to be withheld for Grade 2/3 hypophysitis and discontinued for Grade 4 hypophysitis. Pembrolizumab to be withheld for Grade 2 hypophysitis and withheld or discontinued for Grade 3/4 hypophysitis
- 1mg/kg methylprednisolone (or equivalent) IV to be given daily
  - If given during acute phase, may reverse inflammatory process
- To be followed with prednisone 1-2mg/kg daily with gradual tapering over at least 4 weeks
- Long-term supplementation of affected hormones is often required
  - Secondary hypothyroidism requiring levothyroxine replacement
  - Secondary hypoadrenalism requiring replacement hydrocortisone
  - Typical dose: 20 mg qAM and 10 mg qPM
- Assess risk of opportunistic infection based on duration of steroid taper (and consider prophylaxis if needed)
- Collaborative management approach with endocrinology (particularly if permanent loss of organ function)

Grade 1 (Mild)
- Asymptomatic or mild symptoms; clinical or diagnostic observation only (headache, fatigue)

Grade 2 (Moderate)
- Moderate symptoms; limiting age-appropriate instrumental ADLs (headache, fatigue)

Grade 3 (Severe)
- Severe or medically significant symptoms; limiting self-care ADL (sepsis, severe ataxia)

Grade 4 (Potentially Life-Threatening)
- Urgent intervention required (sepsis, severe ataxia)

Grade 5 (Death)

Nursing Implementation:
- ACTH and thyroid panel should be checked at baseline and prior to each dose of ipilimumab
- Ensure that MRI is ordered with pituitary cuts or via pituitary protocol
- Anticipate treatment with corticosteroid and immunotherapy hold
- Review proper administration of steroid
  - Take with food
  - Take in AM
- Educate patient regarding possibility of permanent loss of organ function (pituitary; possibly others if involved [thyroid, adrenal glands])
- Sick-day instructions, vaccinations, etc

*Steroid taper instructions/calendar as a guide but not an absolute
- Taper should consider patient’s current symptom profile
- Close follow-up in person or by phone, based on individual need & symptomatology
- Anti-acid therapy daily as gastric ulcer prevention while on steroids
- Review steroid medication side effects: mood changes (anger, reactive, hyperaware, euphoric, mania), increased appetite, interrupted sleep, oral thrush, fluid retention
- Be alert to recurring symptoms as steroids taper down & report them (taper may need to be adjusted)

Long-term high-dose steroids:
- Consider antimicrobial prophylaxis (sulfamethoxazole/trimethoprim double dose M/W/F; single dose if used daily) or alternative if sulfa-allergic (e.g., atovaquone [Mepron®] 1500 mg po daily)
- Consider additional antiviral and antifungal coverage
- Avoid alcohol/acetaminophen or other hepatoxins

RED FLAGS:
- Symptoms of adrenal insufficiency

ACTH = adrenocorticotropic hormone; ADLs = activities of daily living; DDX = differential diagnosis; FSH = follicle-stimulating hormone; GH = growth hormone; LH = luteinizing hormone; MRI = magnetic resonance imaging; TSH = thyroid stimulating hormone.

Copyright © 2017 Melanoma Nursing Initiative.
Care Step Pathway – Thyroiditis (inflammation of the thyroid gland)

Nursing Assessment

Look:
- Does the patient appear unwell?
- Changes in weight since last visit
  o Appear heavier? Thinner?
- Changes in hair texture/thickness?
- Appearing hot/cold?
- Does the patient look fatigued?

Listen:
- Appetite/weight changes?
- Hot or cold intolerance?
- Change in energy, mood, or behavior?
- Palpitations?
- Increased fatigue?
- Bowel-related changes?
  o Constipation/diarrhea
- Skin-related changes?
  o Dry/oily

Recognize:
- Ensure that patient undergoes thyroid function tests prior to first dose, every 12 weeks while on PD-1 therapy and q3 weeks with ipilimumab
- High TSH with low free T4 consistent with primary hypothyroidism
- DDX: secondary hypothyroidism due to hypophysitis, low TSH and low free T4
- Occasionally thyroiditis with transient hyperthyroidism (low TSH and high free T4) may be followed by more longstanding hypothyroidism (high TSH and low free T4)
- Other immune-related toxicity?
- Prior thyroid dysfunction?

Type of Thyroid Abnormality

<table>
<thead>
<tr>
<th>TSH low or &lt;0.01 mIU/L with normal or high free T3 or T4</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Acute thyroiditis</td>
</tr>
<tr>
<td>- Rarely Graves’-like disease</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TSH &gt;5, &lt;10 mIU/L with normal free T4, T3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subclinical hypothyroidism</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TSH &gt;10 mIU/L with normal or low free T4 &amp; T3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary hypothyroidism</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TSH low or &lt;0.01 mIU/L with high free T4 or T3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperthyroidism</td>
</tr>
</tbody>
</table>
**Thyroiditis**

**(i)nflammation of the thyroid gland**

**Care Step Pathway**

**Nursing Assessment**

- **Look**:
  - Does the patient appear unwell?
  - Changes in weight since last visit (appear heavier? Thinner?)
  - Changes in hair texture/thickness?
  - Appearing hot/cold?
  - Does the patient look fatigued?

- **Listen**:
  - Appetite/weight changes?
  - Hot or cold intolerance?
  - Change in energy, mood, or behavior?
  - Palpitations?
  - Increased fatigue?
  - Bowel-related changes (constipation/diarrhea)
  - Skin-related changes (dry/oily)

- **Recognize**:
  - Ensure that patient undergoes thyroid function tests prior to first dose, every 12 weeks while on PD-1 therapy and q3 weeks with ipilimumab.
  - High TSH with low free T4 consistent with primary hypothyroidism.
  - DDx: secondary hypothyroidism due to hypophysitis, low TSH and low free T4.
  - Occasionally thyroiditis with transient hyperthyroidism (low TSH and high free T4) may be followed by more longstanding hypothyroidism (high TSH and low free T4).
  - Other immune-related toxicity?
  - Prior thyroid dysfunction?

**Management**

- **TSH low or <0.01 mIU/L with normal or high free T3 or T4**
  - Consider measuring anti-thyroid antibodies and/or TSH-receptor autoantibodies (TRAB) to establish autoimmune etiology.
  - If patient has not received IV iodinated contrast within 2 months, can consider a diagnostic thyroid uptake & scan.
  - Acute thyroiditis usually resolves or progresses to hypothyroidism; thus, can repeat TFTs in 4–6 weeks.
  - If TRAB high, obtain a thyroid uptake scan & refer to endocrinology.
  - Short period of 1 mg/kg prednisone or equivalent may be helpful in acute thyroiditis.
  - Consider use of beta blockers and immunotherapy hold for symptomatic patients (e.g., beta blockers for tachycardia/murmur and immunotherapy holds for patients who have acute thyroiditis threatening an airway). Therapy is often restarted when symptoms are mild/tolerable.

- **TSH >5, <10 mIU/L with normal free T4, T3**
  - Repeat TFTs in 4–6 weeks.

- **TSH >10 with normal or low free T4 & T3**
  - Begin thyroid replacement if symptomatic.
  - May consider repeating levels in 2–4 weeks if asymptomatic.
  - Levothyroxine dose 1.6 mcg per weight (kg) or 75–100 mcg daily.
  - Repeat TSH in 4–6 weeks and titrate dose to reference range TSH.

- **TSH low or <0.01 mIU/L with high free T4 or T3**
  - Consider radioactive iodine therapy or methimazole treatment.
  - Consider use of beta blockers for symptomatic patients (e.g., for tachycardia or murmur).

**Nursing Implementation:**

- Educate patient that hypothyroidism is generally not reversible.
- Assess medication compliance with oral thyroid replacement or suppression.
- History of thyroid disorders does not increase or decrease risk of incidence.
- Consider collaborative management with endocrinologist, especially if the patient is hyperthyroid, particularly if a thyroid scan is needed.

**RED FLAGS:**

- Swelling of thyroid gland causing compromised airway

DDX = differential diagnosis; PD-1 = programmed cell death protein 1; TFT = thyroid function test; TSH = thyroid stimulating hormone.
Care Step Pathway - Type 1 Diabetes Mellitus (immune destruction of beta cells in pancreas)

### Nursing Assessment

**Look:**
- Does the patient appear fatigued?
- Does the patient appear dehydrated?
- Does the breath have a sweet/fruity smell?
- Is the patient tachycardic?

**Listen:**
- Frequent urination?
- Increased thirst?
- Increased hunger?
- Increased fatique?
- Altered level of consciousness with advanced cases

**Recognize:**
- Symptoms of diabetes
- Serum glucose levels
- Other immune-related toxicity
- Infections

### Grading Toxicity (Based on Fasting Glucose)

**Grade 1 (Mild)**
Fasting glucose value >ULN – 160 mg/dL

**Grade 2 (Moderate)**
Fasting glucose value >160 – 250 mg/dL

**Grade 3 (Severe)**
Fasting glucose value >250 – 500 mg/dL, hospitalization indicated

**Grade 4 (Potentially Life-Threatening)**
Fasting glucose value >500 mg/dL, life-threatening consequences

**Grade 5 (Death)**

### Management

**Overall Strategy:**
- Immunotherapy may be withheld until blood glucose is regulated
- Insulin therapy
- Hydration
- Endocrine consult

### Nursing Implementation:

- Discuss that DM1 will likely be permanent
- Review signs and symptoms of hyper/hypoglycemia
- Follow patients closely with checks on blood glucose levels, fruity breath, and other symptoms (e.g., increased infections)
- Assure early intervention
- Provide insulin education (or refer)
- Discuss possibility of other immune-related AEs, including others of endocrine origin

DM = diabetes mellitus; ULN = upper limit of normal
### Care Step Pathway – Pneumonitis (inflammation of lung alveoli)

#### Nursing Assessment

**Look:**
- Does the patient appear uncomfortable?
- Did the patient have difficulty walking to the exam room? Or going up stairs?
- Does the patient appear short of breath?
- Is the patient tachypneic?
- Does the patient appear to be in respiratory distress?

**Listen:**
- Has the patient noted any change in breathing?
- Does the patient feel short of breath?
- Does the patient note new dyspnea on exertion?
- Does the patient notice a new cough? Or a change in an existing cough?
- Have symptoms worsened?
- Are symptoms limiting ADLs?
- Associated symptoms?
  - Fatigue
  - Wheezing

**Recognize:**
- Is the pulse oximetry low? Is it lower than baseline or compared with last visit? Is it low on exertion?
- Is there a pre-existing pulmonary autoimmune condition (i.e., sarcoidosis)?
- Is there a history of prior respiratory compromise (e.g., asthma, COPD, congestive heart failure)?
- Has the patient experienced other immune-related adverse effects?

### Grading Toxicity

**Pneumonitis**

**Definition:** A disorder characterized by inflammation focally or diffusely affecting the lung parenchyma

<table>
<thead>
<tr>
<th>Grade 1 (Mild)</th>
<th>Grade 2 (Moderate)</th>
<th>Grade 3 (Severe)</th>
<th>Grade 4 (Potentially Life-Threatening)</th>
<th>Grade 5 (Death)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic; clinical or diagnostic observations only; intervention not indicated</td>
<td>Symptomatic; medical intervention indicated; limiting instrumental ADLs</td>
<td>Severe symptoms; limiting self-care ADLs; oxygen indicated</td>
<td>Life-threatening respiratory compromise; urgent intervention indicated (tracheostomy, intubation)</td>
<td></td>
</tr>
</tbody>
</table>

**Hypoxia**

**Definition:** A disorder characterized by decrease in the level of oxygen to the body

<table>
<thead>
<tr>
<th>Grade 1 (Mild)</th>
<th>Grade 2 (Moderate)</th>
<th>Grade 3 (Severe)</th>
<th>Grade 4 (Potentially Life-Threatening)</th>
<th>Grade 5 (Death)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decreased oxygen saturation with exercise (e.g., pulse ox &lt;88%); intermittent supplemental oxygen</td>
<td>Decreased oxygen saturation at rest (e.g., pulse ox &lt;88%)</td>
<td></td>
<td>Life-threatening airway compromise; urgent intervention indicated (tracheostomy, intubation)</td>
<td></td>
</tr>
</tbody>
</table>
**Management**

**Overall Strategy:**
- Assess for other etiologies such as infection, pulmonary embolism, progressive lung metastases, or lung disease
- Early intervention to maintain or improve physical function and impact on QOL
- Assess pulse oximetry (resting & on exertion) at baseline and at each visit to assist in identifying a decrease at early onset.

<table>
<thead>
<tr>
<th>Prevention</th>
<th>Grade 1 (Mild)</th>
<th>Grade 2 (Moderate)</th>
<th>Grades 3–4 (Severe or Life-Threatening)</th>
</tr>
</thead>
<tbody>
<tr>
<td>- No known interventions</td>
<td>- Anticipate immunotherapy to continue</td>
<td>- Immunotherapy to be withheld for Grade 2 events (resume when Grade 0/1)</td>
<td>- Discontinue immunotherapy for Grade 3/4 events</td>
</tr>
<tr>
<td></td>
<td>- Continue to monitor via radiology testing (q 2–4 weeks, as needed)</td>
<td>- Immunotherapy to be discontinued for recurrent (pembrolizumab, nivolumab) or persistent Grade 2 events (ipilimumab, pembrolizumab, nivolumab)</td>
<td>- Patient will likely need to be admitted to the hospital for further management and supportive care</td>
</tr>
<tr>
<td></td>
<td>- Review symptoms to watch for with patient and family, and remember to assess at every subsequent visit</td>
<td>- Anticipate treatment with:</td>
<td>- Anticipate the use of high-dose IV corticosteroids (e.g., methylprednisolone 2–4 mg/kg/day or equivalent)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Corticosteroids (e.g., prednisone 1–2 mg/kg/day or equivalent) until symptoms improve to baseline, and then slow taper over at least 1 month</td>
<td>- Once symptoms have resolved to baseline or Grade 1, convert to equivalent oral corticosteroid dose and then taper slowly over at least 1 month</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- If symptoms do not improve within 48–72 hours, corticosteroid dose will be escalated. IV corticosteroids may be considered</td>
<td>- Anticipate the use of empiric antibiotics until infection is excluded</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Additional supportive care medications may also be initiated</td>
<td>- Anticipate the use of additional immunosuppressive agents if symptoms do not improve in 48–72 hours (e.g., infliximab, mycophenolate, cyclophosphamide)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Anticipatory guidance on proper administration</td>
<td>- Assess patient &amp; family understanding of toxicity and rationale for treatment discontinuation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Anticipate that bronchoscopy may be ordered by provider</td>
<td>- Identify barriers to adherence, specifically compliance with medication, physical activity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Assess patient &amp; family understanding of recommendations and rationale</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Identify barriers to adherence</td>
<td></td>
</tr>
</tbody>
</table>

**Nursing Implementation:**
- Identify high-risk individuals (e.g., asthma, COPD) and those with cardiopulmonary symptoms prior to initiating immunotherapy. Establish a thorough baseline
- Educate patients that new pulmonary symptoms should be reported immediately
- Anticipate that the steroid requirements to manage pneumonitis are high (1–4 mg/kg/day) and patient will be on corticosteroid therapy for at least 1 month
- Educate patients and family about the rationale for discontinuation of immunotherapy in patients who do develop moderate or severe pneumonitis

**RED FLAGS:**
- Risk of acute onset
- Risk of mortality if pneumonitis treatment is delayed
- Risk of pneumonitis is greater in patients receiving combination immunotherapy regimens

ADL = activities of daily living; COPD = chronic obstructive pulmonary disease
**Care Step Pathway - Arthralgias and Arthritis**

### Nursing Assessment

**Look:**
- Does the patient appear uncomfortable?
- Does the patient appear unwell?
- Is their gait affected?
- Obvious swollen, or deformed joint(s)?
- Is the patient having trouble getting up and down stairs?

**Listen:**
- Have symptoms worsened?
- Are symptoms limiting ADLs?
- Are symptoms increasing the patient’s risk for fall? Other safety issues?
- Associated symptoms?
  - Fatigue (new or worsening)

**Recognize:**
- Is there a pre-existing autoimmune dysfunction?
- Is there a history of prior orthopedic injury, DJD, OA, RA?
- Other immune-related adverse effects
- Three subtypes of inflammatory arthritis associated with checkpoint inhibitors:
  1. Polyarthritis similar to rheumatoid arthritis
  2. True reactive arthritis with conjunctivitis, urethritis, and oligoarthritis
  3. Subtype similar to seronegative spondyloarthritis with inflammatory back pain and predominantly larger joint involvement.

### Grading Toxicity

**Arthralgia**
Definition: A disorder characterized by a sensation of marked discomfort in a joint

<table>
<thead>
<tr>
<th>Grade 1 (Mild)</th>
<th>Grade 2 (Moderate)</th>
<th>Grade 3 (Severe)</th>
<th>Grade 4 (Potentially Life-Threatening)</th>
<th>Grade 5 (Death)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild pain</td>
<td>Moderate pain; limiting instrumental ADL</td>
<td>Severe pain; limiting self-care ADL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Arthritis**
Definition: A disorder characterized by inflammation involving a joint

<table>
<thead>
<tr>
<th>Grade 1 (Mild)</th>
<th>Grade 2 (Moderate)</th>
<th>Grade 3 (Severe)</th>
<th>Grade 4 (Potentially Life-Threatening)</th>
<th>Grade 5 (Death)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild pain with inflammation, erythema, or joint swelling</td>
<td>Moderate pain associated with signs of inflammation, erythema, or joint swelling; limiting instrumental ADL</td>
<td>Severe pain associated with signs of inflammation, erythema, or joint swelling; irreversible joint damage; disabling; limiting self-care ADL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Management

**Overall Strategy:**
- Assess for other etiologies, such as lytic or osseous metastasis
- Early intervention to maintain or improve physical function and impact on QOL; symptom control through the treatment of inflammation and pain is often achieved with NSAIDs, corticosteroids, and other adjunct therapies

<table>
<thead>
<tr>
<th>Prevention</th>
<th>Grade 1 (Mild)</th>
<th>Grade 2 (Moderate)</th>
<th>Grades 3-4 (Severe or Life-Threatening)</th>
</tr>
</thead>
<tbody>
<tr>
<td>- No known interventions</td>
<td>- Anticipate immunotherapy to continue</td>
<td>- Ipilimumab to be withheld for any Grade 2 event (until Grade 0/1) and discontinued for events persisting ≥6 weeks or inability to reduce steroid dose to 7.5 mg prednisone or equivalent per day</td>
<td>- Pembrolizumab or nivolumab to be withheld for first-occurrence Grade 3/4 event and discontinued if:</td>
</tr>
<tr>
<td></td>
<td>- Encourage physical activity</td>
<td>- Dose of pembrolizumab or nivolumab to be held as to not make symptoms worse</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Pembrolizumab or nivolumab to be discontinued for Grade 2 events persisting ≥12 weeks</td>
<td>o Grade 3/4 event recurs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Continue to encourage physical activity</td>
<td>o Persist ≥12 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Anticipate use of analgesia</td>
<td>- Ipilimumab to be discontinued for any Grade 3/4 event.</td>
</tr>
<tr>
<td></td>
<td>o Low-dose NSAIDs</td>
<td>o NSAIDs</td>
<td>- High-dose steroids to be used (1-1.5 mg/kg) daily; [rapid effect within days]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Topical: diclofenac (gel or patch). Best for localized, limited, superficial joint inflammation or for use in patients who cannot tolerate oral NSAIDs</td>
<td>o Anticipatory guidance on proper administration</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Oral: ibuprofen, naproxen, celecoxib</td>
<td>o Onset of action is rapid, typically within days</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Anticipate referral to rheumatology for collaborative management and consideration of adjunct treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o Non-biologic agents (more likely to be recommended)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ Conventional synthetic DMARDs (cDMARDs), which have a delayed effect and take weeks to work:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o Biologic agents (less likely to be recommended)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ Biologic DMARDs (bDMARDs)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ TNF inhibitors</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o Anti B-cell agents (CD-20 blocking)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o Agents NOT advised</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o Assess patient &amp; family understanding of toxicity and rationale for treatment discontinuation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o Identify barriers to adherence, specifically compliance with medication, physical activity</td>
</tr>
</tbody>
</table>

If symptoms do not improve in 4–6 weeks, escalate to next level of therapy

*If symptoms do not improve in 4–6 weeks, escalate to next level of therapy

No known interventions
Nursing Implementation:
- Identify high-risk individuals and those with underlying autoimmune dysfunction
- Educate patients that arthralgias and arthritis are the most commonly reported rheumatic and musculoskeletal irAEs with checkpoint inhibitors
- Arthritis-like symptoms can range from mild (managed well with NSAIDs and low dose corticosteroids) to severe and erosive (requiring multiple immunosuppressant medications)
- Anticipate that the steroid requirements to manage arthralgias can be much higher (i.e., up to 1.5 mg/kg/day) than typically required to manage "classic" inflammatory arthritis
- Educate patients that symptoms can persist beyond treatment completion or discontinuation

RED FLAGS:
- Risk of fall due to mobility issue

ADLs = activities of daily living; ANA = antinuclear antibody; BUN = blood urea nitrogen; CBC = complete blood count; CR = creatinine; CRP = C-reactive protein; DJD = degenerative joint disease; DMARD = disease-modifying antirheumatic drug; ESR = erythrocyte sedimentation rate; NSAID = nonsteroidal anti-inflammatory drug; OA = osteoarthritis; QOL = quality of life; RA = rheumatoid arthritis; RF = rheumatoid factor; TNF = tumor necrosis factor
Care Step Pathway – Neuropathy (motor or sensory nerve impairment or damage)

Nursing Assessment

Look:
- Does the patient appear weak?
- Does the patient appear uncomfortable?
- Altered ambulation or general movement?
- If muscular weakness is present, any respiratory difficulties apparent?

Listen:
- Does the patient report weakness (unilateral or bilateral)?
- Does the patient report new or worsened pain, numbness, or tingling?
- Does the patient report difficulty walking or holding items?

Recognize:
- Motor deficits
- Sensory deficits
- Mental status changes
- Paresthesia
- Laboratory values
- Does the patient have diabetes mellitus?
- Are there neurologic signs and symptoms?
- Results of prior imaging
  - Metastases to spinal cord
  - Other metastases that may cause symptoms

Grading of Neuropathy:

<table>
<thead>
<tr>
<th>Grade 1 (Mild)</th>
<th>Grade 2 (Moderate)</th>
<th>Grade 3 (Severe)</th>
<th>Grade 4 (Potentially Life-Threatening)</th>
<th>Grade 5 (Death)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral Motor:</td>
<td>Peripheral Motor:</td>
<td>Peripheral Motor:</td>
<td>Peripheral Motor:</td>
<td></td>
</tr>
<tr>
<td>Asymptomatic; clinical or diagnostic observations only</td>
<td>Moderate symptoms; limiting ADLs</td>
<td>Severe symptoms; limiting self-care ADLs, requires assistive devices</td>
<td>Life-threatening; urgent intervention indicated</td>
<td></td>
</tr>
<tr>
<td>Peripheral Sensory:</td>
<td>Peripheral Sensory:</td>
<td>Peripheral Sensory:</td>
<td>Peripheral Sensory:</td>
<td></td>
</tr>
<tr>
<td>Asymptomatic; loss of deep tendon reflexes or paresthesia</td>
<td>Moderate symptoms; limiting ADLs</td>
<td>Severe symptoms; limiting self-care ADLs</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Management

Overall Strategy:
- Rule out infectious, non-infectious, disease-related etiologies
- High-dose steroids (1–2 mg/kg/day prednisone or equivalent) to be used
- Ipilimumab to be withheld for Grade 2 event, nivolumab for first occurrence of Grade 3 event, and pembrolizumab based on disease severity; ipilimumab to be discontinued for Grade 2 events persisting ≥6 weeks or inability to reduce steroid dose to ≤7.5 mg prednisone or equivalent per day; pembrolizumab or nivolumab to be discontinued for Grade 3/4 events that recur, persist ≥12 weeks, or inability to reduce steroid dose to ≤10 mg prednisone or equivalent per day
- Neurology consult
  - Consideration of electromyelogram and nerve conduction tests
  - Immune globulin infusions
  - Plasmapheresis
- Taper steroids slowly over at least 4 weeks once symptoms improve
- If needed, obtain physical therapy or occupational therapy consult (for both functional assessment and evaluate safety of patient at home)
- Supportive medications for symptomatic management

- Neurology consult
  - Metastases to spinal cord
  - Other metastases that may cause symptoms

© 2017 The Melanoma Nursing Initiative. All rights reserved
www.themelanomanurse.org
Nursing Implementation:
- Compare baseline assessment; grade & document neuropathy and etiology (diabetic, medication, vascular, chemotherapy)
- Early identification and evaluation of patient symptoms
- Early intervention with lab work and office visit if neuropathy symptoms suspected

*Steroid taper instructions/calendar as a guide but not an absolute
- Taper should consider patient’s current symptom profile
- Close follow-up in person or by phone, based on individual need & symptomatology
- Anti-acid therapy daily as gastric ulcer prevention while on steroids
- Review steroid medication side effects: mood changes (anger, reactive, hyperaware, euphoric, mania), increased appetite, interrupted sleep, oral thrush, fluid retention
- Be alert to recurring symptoms as steroids taper down & report them (taper may need to be adjusted)

Long-term high-dose steroids:
- Consider antimicrobial prophylaxis (sulfamethoxazole/trimethoprim double dose M/W/F; single dose if used daily) or alternative if sulfa-allergic (e.g., atovaquone [Mepron®] 1500 mg po daily)
- Consider additional antiviral and antifungal coverage
- Avoid alcohol/acetaminophen or other hepatoxins

RED FLAGS:
- Guillain–Barré syndrome
- Myasthenia gravis

ADLs = activities of daily living
Nursing Assessment

Look:
- Does the patient appear uncomfortable?
- Does the patient look ill?

Listen:
- Has there been change in urination?
  o Urine color?
  o Frequency?
- How much fluid is the patient taking in?
- Are associated symptoms present?
  o Nausea?
  o Headache?
  o Malaise?
  o Lung edema?
- Are there symptoms concerning for:
  o Urinary tract infection?
  o Pyelonephritis?
  o Worsening CHF?
- Are symptoms limiting ADLs?
- Current or recent use of nephrotoxic medications
  (prescribed and OTC) other agents?
  o NSAIDs
  o Antibiotics
  o Contrast media or other nephrotoxic agents
    (contrast dye, aminoglycosides, PPI)?

Recognize:
- Laboratory abnormalities (elevated creatinine, electrolyte abnormalities)
- Urinalysis abnormalities (casts)
- Abdominal or pelvic disease that could be causing symptoms
- Prior history of renal compromise?
- Other immune-related adverse effects?
- Presence of current or prior immune-mediated toxicities, including rhabdomyolysis
- Is patient volume depleted?

Grading Toxicity

**Acute Kidney Injury, Elevated Creatinine**
Definition: A disorder characterized by the acute loss of renal function and is traditionally classified as pre-renal, renal, and post-renal.

<table>
<thead>
<tr>
<th>Grade 1 (Mild)</th>
<th>Grade 2 (Moderate)</th>
<th>Grade 3 (Severe)</th>
<th>Grade 4 (Potentially Life-Threatening)</th>
<th>Grade 5 (Death)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creatinine level &gt;0.3 mg/dL; creatinine 1.5–2× ULN</td>
<td>Creatinine 2–3× ULN</td>
<td>Creatinine &gt;3× ULN or &gt; 4.0 mg/dL; hospitalization indicated</td>
<td>Life-threatening consequences; dialysis indicated</td>
<td></td>
</tr>
</tbody>
</table>

Care Step Pathway – Nephritis (inflammation of the kidneys)
**Management**

**Overall Strategy**
- Assess for other etiologies, such as infection
- Eliminate potentially nephrotoxic medications
- Ensure adequate hydration daily
- Evaluate for progressive kidney/adrenal/pelvic metastases that may be contributing to kidney dysfunction
- Early intervention to maintain or improve physical function and impact on QOL

**Mild elevation in creatinine (Grade 1)**
- Anticipate immunotherapy to continue
- Perform detailed review of concomitant medications (prescribed and OTC), herbs, vitamins, anticipating possible discontinuation of nephrotoxic agents
- Avoid/minimize addition of nephrotoxic agents, such as contrast media for radiology tests
- Anticipate close monitoring of creatinine (i.e., weekly)
- Educate patient/family on importance of adequate daily hydration and set individualized hydration goals
- Review symptoms to watch for with patient and family and remember to assess at subsequent visits

**Moderate elevation in creatinine (Grade 2)**
- Ipilimumab to be withheld for any Grade 2 event (until Grade 0/1) and discontinued for events persisting ≥6 weeks or inability to reduce steroid dose to 7.5 mg prednisone/day
- Pembrolizumab or nivolumab to be withheld for Grade 2 events persisting ≥12 weeks or inability to reduce steroid dose to ≤10 mg prednisone or equivalent per day
- Anticipate increase in frequency of creatinine monitoring (i.e., every 2–3 days until improvement)
- Immunosuppressive medications to be initiated to treat immune-mediated nephritis
  - Systemic corticosteroids (e.g., prednisone) 0.5–1 mg/kg/day until symptom improve to baseline followed by slow taper over at least 1 month
  - Anticipate increased in corticosteroid dosing (i.e., treat as if Grade 3 nephritis) if creatinine does not improve within 48–72 hours
- Anticipate use of additional supportive care medications
- Upon symptoms resolution to patient’s baseline, or Grade 1, begin to taper corticosteroid dose slowly over 1 month
- Anticipatory guidance on proper administration
- Anticipate the use of IV fluid to ensure adequate hydration
- Anticipate that nephrology consultation may be initiated by provider
- Assess patient & family understanding of recommendations and rationale
- Identify barriers to adherence

**Moderate (Grade 3) and Severe (Grade 4)**
- Pembrolizumab or nivolumab to be withheld for first-occurrence Grade 3/4 event and discontinued if:
  - Grade 3/4 event recurs
  - Persists ≥12 weeks
  - Requires >10 mg prednisone or equivalent per day for more than 12 weeks.
- Ipilimumab to be discontinued for any Grade 3/4 event
- Immunosuppressive medications to be initiated to treat immune-mediated nephritis
  - Corticosteroids (e.g., prednisone 1–2 mg/kg/day, in divided doses) until symptoms improve to baseline and then slow taper over at least 1 month
  - If symptoms do not improve within 48–72 hours, additional immunosuppressive medications will be considered
- Anticipate nephrology consultation will be initiated by provider
- Anticipate that renal biopsy will be considered
- Hemodialysis may be considered
- Anticipate possible hospital admission for Grade 4 elevations in creatinine or in patients with multiple comorbidities
Risk of immune-mediated nephritis is greater in patients receiving combination immunotherapy regimens and PD-1 inhibitors
- Risk of mortality if unrecognized or treatment is delayed
- In addition to acute interstitial nephritis seen from PD-1 inhibitors, there are case reports of lupus-like nephritis and granulomatous acute interstitial nephritis

ADLs = activities of daily living; CHF = congestive heart failure; LE = lung edema; NSAIDs = nonsteroidal anti-inflammatory drugs; OTC = over the counter; PPI = proton pump inhibitor; QOL = quality of life; ULN = upper limit of normal.
APPENDIX 2
## Management of other AEs associated with ipilimumab therapy

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Common symptoms</th>
<th>Common management/anticipatory guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute respiratory distress syndrome</td>
<td>Severe shortness of breath, dyspnea, or rapid breathing, hypotension, confusion, and extreme fatigue</td>
<td>• Serious condition requiring hospitalization/expert care, including supplemental oxygen, often mechanical ventilation, and fluid management</td>
</tr>
</tbody>
</table>
| Anorexia                              | Decreased appetite                                                              | • Monitor weight; query patient about appetite/eating habits; advise dietary modification if necessary (should improve with time)  
• Anticipate standard dose holds/discontinuations*  
• Consider referral to nutrition services for counseling on best food choices to avoid excessive weight loss |
| Cardiotoxicity: cardiomyopathy, myocarditis, heart failure | Dyspnea, edema, fatigue, chest pain, arrhythmias, abdominal pain or ascites     | • Monitor weight, changes in breathing, extremity edema, chest/back/arm/jaw pain, pressure  
• ECG, Echo, stress test cardiology referral, 2 mg/kg prednisone, discontinue therapy |
| Embryo-fetal toxicity                 | —                                                                               | • Advise of risk to fetus and recommend use of effective contraception during treatment and for 3 months after ipilimumab and for 5 months after nivolumab is discontinued  
• Advise patient to tell HCP immediately if they or their partner suspect they are pregnant while taking therapy |
| Encephalitis                          | Headache, fever, tiredness, confusion, memory problems, sleepiness, hallucinations, seizures, stiff neck | • New-onset (Grade 2–3) moderate to severe symptoms: rule out infectious or other causes; consult neurologist, obtain brain MRI, and lumbar puncture  
• For ipilimumab: Anticipate standard ipilimumab dose holds/discontinuations*; administer corticosteroids at dose of 1–2 mg/kg/d prednisone equivalents (or 2–4 mg/kg if necessary)  
• For nivolumab: Withhold nivolumab for new-onset moderate to severe neurologic symptoms; evaluate as described above; if other etiologies are ruled out, administer corticosteroids and permanently discontinue nivolumab for immune-mediated encephalitis |
| Fatigue                               | Feeling tired; lack of energy                                                    | • Query patients regarding energy level; evaluate possible contributory factors, including infection, disease progression, and hematological and metabolic abnormalities; standard supportive care  
• Anticipate standard dose holds/discontinuations*  
• Fatigue that interferes with ADLs is concerning and should be evaluated for underlying causes |
### Management of other AEs associated with ipilimumab therapy

(Continued)

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Common symptoms</th>
<th>Common management/anticipatory guidance</th>
</tr>
</thead>
</table>
| **Headache**                | Head pain                                                                       | • Need to rule out brain metastases, encephalitis, or hypophysitis; otherwise, standard supportive care (should improve with time)  
• Headache occurring in conjunction with fatigue could be indicative of hypophysitis  
• Anticipate standard dose holds/discontinuations*                                                                 |
| **Infusion reaction**       | Chills/shaking, back pain, itching, flushing, difficulty breathing, hypotension, fever | • Nivolumab and/or ipilimumab: For mild/moderate (Grade 1–2) reactions: interrupt or slow rate of infusion; monitor to recovery.  
• For severe/life-threatening (Grade 3–4) reactions: Discontinue nivolumab and/or ipilimumab; manage anaphylaxis via institutional protocol; monitor. Premedication with an antipyretic and antihistamine may be considered for future doses |
| **Insomnia**                | Difficulty falling or staying asleep                                             | • Counsel patients on good sleep habits; prescription medications can be used if needed (should improve over time)  
• May be related to steroid use  
• Anticipate standard dose holds/discontinuations*                                                                 |
| **Nausea/vomiting**         | Vomiting, queasiness, RUQ or LUQ pain                                           | • May indicate hepatotoxicity; check LFTs/lipase/amylase; standard supportive care  
• Anticipate dose holds/discontinuations*                                                                 |
| **Ocular:** conjunctivitis, blepharitis, episcleritis, iritis, ocular myositis, scleritis, uveitis (associated with ipilimumab)** | Blurry vision, double vision, or other vision problems, eye pain or redness | • Encourage patient to report any eye symptoms immediately  
• Obtain ophthalmology referral  
• Anticipate standard dose ipilimumab holds/discontinuations*                                                                 |
| **Pyrexia**                 | Elevated body temperature                                                       | • Standard supportive care related to cytokine release  
• Consider infectious workup for prolonged elevated temperature  
• Anticipate standard dose holds/discontinuations*                                                                 |
| **Rhabdomyolysis**         | Pain, muscle weakness, vomiting, confusion, tea-colored urine                  | • Anticipate does holds/discontinuations*  
• Intravenous fluids and corticosteroids (check creatine kinase levels)                                                                 |

*Withhold ipilimumab for any G2 (moderate) AE, and resume treatment when AE returns to G0 or 1; permanently discontinue for any G3–4 (life-threatening) AE, persistent G2 AE lasting ≥6 weeks, or inability to reduce corticosteroid dose to 7.5 mg/d prednisone or equivalent.